SPY
778.53
−0.01%
QQQ
751.27
0.00%
BTC/USD
82,553.27
+1.05%
DIA
516.00
−0.02%
GLD
384.08
−0.13%
TLT
77.95
−0.04%
US
Sign in
Register
My Account
Benzinga
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
LifeMD Inc
LFMD
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.63
-0.02
-0.75%
Last update: Oct 9, 6:42 PM
$2.64
-0.01
-0.38%
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Compare
Options
Stock Report
Privacy Manager
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
LifeMD Financials
LifeMD (LFMD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
LifeMD Lowers FY2026 Sales Guidance from $220.000M-$230.000M to $205.500M-$212.500M vs $222.046M Est
LifeMD (NASDAQ:LFMD) lowers FY2026 sales outlook from $220.000 million-$230.000 million to $205.500 million-$212.500 million vs $222.046 million estimate.
Benzinga Newsdesk
PRO
LifeMD Sees Q3 Sales $48.000M-$51.000M vs $58.547M Est
LifeMD (NASDAQ:LFMD) sees Q3 sales of $48.000 million-$51.000 million vs $58.547 million analyst estimate.
Benzinga Newsdesk
PRO
LifeMD Q2 EPS $(0.16) Misses $(0.15) Estimate, Sales $47.300M Miss $49.152M Estimate
LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 166.67 percent decrease over losses of $(0.06) per share from the
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
LifeMD Affirms FY2026 Sales Guidance of $220.000M-$230.000M vs $223.588M Est
LifeMD (NASDAQ:LFMD) affirms FY2026 sales outlook from $220.000 million-$230.000 million to $220.000 million-$230.000 million vs $223.588 million estimate.
Benzinga Newsdesk
PRO
LifeMD Sees Q2 Sales $47.000M-$50.000M vs $53.989M Est
LifeMD (NASDAQ:LFMD) sees Q2 sales of $47.000 million-$50.000 million vs $53.989 million analyst estimate.
Benzinga Newsdesk
